Put Arrhythmia Warnings for Lamotrigine in Context

A new FDA warning will spur questions about the risk of serious arrhythmias with lamotrigine (Lamictal).

Labeling now cautions to weigh lamotrigine risks and benefits in patients with ischemic CV damage (prior MI, etc)...structural or functional disease (heart failure, AV block, etc)...or multiple CV risks.

It stems from lab data showing that lamotrigine’s effects on cardiac sodium channels could widen the QRS interval...and from case reports linking lamotrigine to ECG changes or cardiac arrest.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote